AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The ...

AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

VENCLEXTA (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their ...

AbbVie seeks FDA approval for a groundbreaking oral treatment combining venetoclax and acalabrutinib, promising a new era in ...

AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...

AbbVie ABBV is set to report second-quarter 2025 earnings on July 31, before the opening bell. The Zacks Consensus Estimate ...

Joseph Michael Roche died peacefully on July 11, 2025, in Naperville, Illinois, surrounded by family. He was 81 years old. Joe was born on March 23, 1944, in Philadelphia, Pennsylvania, to the late… ...

The cause of death has been revealed for Prince William and Harry’s 20-year-old cousin Rosie Roche, roughly a week after she was found dead with a firearm nearby.

Genentech's Lunsumio+Polivy combo reduces disease progression risk by 59% in relapsed large B-cell lymphoma. Read more here.

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.